The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Trial Profile

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms LIRABONE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019.
    • 27 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top